Ain Shams University, Cairo, Egypt.
Ophthalmic Res. 2013;49(1):20-4. doi: 10.1159/000341734. Epub 2012 Sep 13.
To evaluate the efficacy and safety of intrasilicone injection of bevacizumab for the treatment of iris neovascularization after vitrectomy for proliferative diabetic retinopathy.
Bevacizumab 1.25 mg/0.05 ml was injected into silicone oil in 15 eyes of 11 patients with iris neovascularization which had developed 2.5-6 months after vitrectomy and silicone oil tamponade. The main outcome measures were regression of iris neovascularization, intraocular pressure elevation, and visual acuity.
In all eyes, iris neovascularization regressed and postinjection intraocular pressure was controlled within 7 days postinjection. Visual acuity improved in 12 eyes. In 4 patients, iris neovascularization recurred within 10 weeks after the injection and they were successfully treated with a second intrasilicone bevacizumab injection of the same dose.
Intrasilicone injection of bevacizumab is safe and effective in the treatment of patients with iris neovascularization after vitrectomy for advanced proliferative diabetic retinopathy. Further studies on greater numbers of patients and more advanced neovascularization are recommended.
评估玻璃体内注射贝伐单抗联合硅油填充治疗增生性糖尿病视网膜病变玻璃体切除术后虹膜新生血管的疗效和安全性。
11 例 15 眼增生性糖尿病视网膜病变玻璃体切除术后 2.5-6 个月发生虹膜新生血管的患者，玻璃体内注射贝伐单抗 1.25mg/0.05ml 至硅油中。主要观察指标为虹膜新生血管消退、眼压升高和视力变化。
所有患眼的虹膜新生血管均消退，注药后 7 天内眼压得到控制。12 眼视力提高。4 例患者注药后 10 周内虹膜新生血管复发，再次行相同剂量玻璃体内注射贝伐单抗硅油填充治疗后成功。
玻璃体内注射贝伐单抗联合硅油填充治疗增生性糖尿病视网膜病变玻璃体切除术后虹膜新生血管安全有效，对于更严重的虹膜新生血管病变需要进一步研究。
